The FDA has discontinued Risk Evaluation and Mitigation Strategies (REMS) for six CAR-T cell therapies targeting BCMA and CD19, used in multiple myeloma, leukemia, and lymphoma. This decision reflects accumulated real-world evidence and established management guidelines for risks like cytokine release syndrome and neurotoxicity, facilitating broader access and enabling use in community centers. FDA leadership hailed the move as a streamlined pathway to expedite delivery of these potentially curative cell therapies while lessening provider burdens. The reduction in post-treatment monitoring times further underscores a regulatory shift toward integration and acceleration of cell therapy treatments.